GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Total Receivables

Regnum (Regnum) Total Receivables : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Regnum Total Receivables?

Regnum's Total Receivables for the quarter that ended in Mar. 2023 was $0.00 Mil.


Regnum Total Receivables Historical Data

The historical data trend for Regnum's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Total Receivables Chart

Regnum Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Receivables
Get a 7-Day Free Trial - - 0.01 - -

Regnum Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.09 - - -

Regnum Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Regnum Total Receivables Related Terms

Thank you for viewing the detailed overview of Regnum's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Regnum (Regnum) Business Description

Traded in Other Exchanges
N/A
Address
600 Third Avenue, 19th Floor, New York, NY, USA, 10016
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines